BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
114.24
+0.65 (0.57%)
Last updated: Aug 15, 2025
0.57%
Market Cap48.41B
Revenue (ttm)1.19B
Net Income (ttm)138.06M
Shares Out422.40M
EPS (ttm)0.33
PE Ratio350.64
Forward PE184.84
Dividend0.10 (0.08%)
Ex-Dividend DateJun 23, 2025
Volume4,571,300
Average Volume15,013,832
Open113.58
Previous Close113.59
Day's Range112.00 - 117.55
52-Week Range22.82 - 122.59
Beta0.30
RSI71.77
Earnings DateAug 29, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,151
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.

Financial Statements

News

There is no news available yet.